638 related articles for article (PubMed ID: 25494457)
1. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
[TBL] [Abstract][Full Text] [Related]
2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
3. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
4. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
[TBL] [Abstract][Full Text] [Related]
5. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
6. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
[TBL] [Abstract][Full Text] [Related]
8. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
Wong G; Qiu X
Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp).
Barrenas F; Green RR; Thomas MJ; Law GL; Proll SC; Engelmann F; Messaoudi I; Marzi A; Feldmann H; Katze MG
Clin Vaccine Immunol; 2015 Mar; 22(3):354-6. PubMed ID: 25589554
[TBL] [Abstract][Full Text] [Related]
10. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
[TBL] [Abstract][Full Text] [Related]
11. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability.
Zhang Y; Wei Y; Li Y; Wang X; Liu Y; Tian D; Jia X; Gong R; Liu W; Yang L
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0008403. PubMed ID: 33711011
[TBL] [Abstract][Full Text] [Related]
12. Role of natural killer cells in innate protection against lethal ebola virus infection.
Warfield KL; Perkins JG; Swenson DL; Deal EM; Bosio CM; Aman MJ; Yokoyama WM; Young HA; Bavari S
J Exp Med; 2004 Jul; 200(2):169-79. PubMed ID: 15249592
[TBL] [Abstract][Full Text] [Related]
13. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
14. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
15. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
[TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
17. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
18. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
20. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
